Pharmafile Logo
Pharmafocus logo
Advanced Search

pharma

Showing 15 posts of 2914 posts found.

FDA U-turns to approve Sarepta’s Vyondys 53 in Duchenne muscular dystrophy

December 13, 2019
Medical Communications, Sales and Marketing FDA, Vyondys 53, pharma, sarepta

The FDA has surprised industry pundits by choosing to approve Sarepta’s Vyondys 53 under an accelerated pathway for the treatment …

News
roche

Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

December 12, 2019
Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …

News
china-1081714_1920

China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer

December 12, 2019
Sales and Marketing AstraZeneca, Imfinzi, pharma

AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …

News
shutterstock_512649

New NAFTA terms put hold on Canadian drug prices

December 11, 2019
Research and Development, Sales and Marketing Canada, NAFTA, US, pharma

NAFTA members have agreed to remove a provision that would have increased protections on biologics drugs. This means Canada, despite …

News
6127243966_e9189f1099_b

Multiple sclerosis market to be worth $32.9bn in 2028

December 11, 2019
Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …

News
fdaoutsideweb

Correvio’s atrial fibrillation drug voted down by FDA committee over safety concerns

December 11, 2019
Research and Development, Sales and Marketing Correvio Pharma, FDA, atrial fibrillation, pharma

It has emerged that Correvio Pharma’s anti-arrhythmic therapy Brinavess was shot down by the FDA’s Cardiovascular and Renal Drugs Advisory …

News

Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia

December 11, 2019
Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma

Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …

News
msd

MSD set to acquire ArQule in deal worth up to $2.7 billion

December 10, 2019
Manufacturing and Production, Medical Communications, Sales and Marketing MSD, acquisition, arqule, pharma

MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …

News
janssen_latest_logo_on_sign

Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma

Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …

News
abbvie_0

Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …

News
shutterstock_138095450

Transactions in the pharma sector: Through the EU merger review looking-glass

December 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …

Feature
jj

J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …

News
sage_logo

Sage Therapeutics’ depression drug falls short at Phase 3

December 6, 2019
Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure

Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …

News
novartis_gilenya_multiple_sclerosis_2

FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis

December 6, 2019
Medical Communications, Sales and Marketing Novartis, generics, gilenya, multiple sclerosis, pharma

The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult …

News

Partnership with payers: Communicating and negotiating with impact

December 6, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NDA, market access, pharma

NDA’s Lisa Peluso, Director, Coaching and Client Engagement, outlines key strategies for interacting with audiences and payers while maximising team …

News
The Gateway to Local Adoption Series

Latest content

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026